Overweight, obesity increase risk of cardiotoxicity from anthracyclines
Being overweight or obese was significantly associated with a greater risk of developing cardiotoxicity among breast cancer patients treated with anthracyclines and/or trastuzumab, investigators...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Eating Disorders & Weight Management | Family Practices | Heart | Herceptin | Obesity | Primary Care